BioVersys AG (XSWX:BIOV) Total Liabilities: CHF30.83 Mil (As of Dec. 2025)


XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF26.30
View Full Analysis

What is BioVersys AG Total Liabilities?

BioVersys AG XSWX:BIOV -2.59% 4 Total Liabilities is CHF30.83 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's Total Liabilities for the quarter that ended in Dec. 2025 was CHF30.83 Mil.

BioVersys AG's quarterly Total Liabilities increased from Dec. 2024 (CHF24.27 Mil) to Jun. 2025 (CHF24.85 Mil) and increased from Jun. 2025 (CHF24.85 Mil) to Dec. 2025 (CHF30.83 Mil).

BioVersys AG's annual Total Liabilities increased from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF24.27 Mil) and increased from Dec. 2024 (CHF24.27 Mil) to Dec. 2025 (CHF30.83 Mil).

BioVersys AG Total Liabilities Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Liabilities Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Total Liabilities
24.27 30.83

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Total Liabilities 0.00 24.27 24.85 30.83
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioVersys AG's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.896+(21.44+-2.7755575615629E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.489+0)
=30.83

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=90.636-59.811
=30.83

BioVersys AG's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.896+(21.44+-2.7755575615629E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.489+0)
=30.83

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=90.636-59.811
=30.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of CHF30.83 Mil mean?
BioVersys AG (XSWX:BIOV) has a Total Liabilities of CHF30.83 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BioVersys AG and its competitors.
Is BioVersys AG's Total Liabilities too high?
BioVersys AG's current Total Liabilities is CHF30.83 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Total Liabilities compare to VRTX and REGN?
BioVersys AG's Total Liabilities of CHF30.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BioVersys AG and its competitors. BioVersys AG's current Total Liabilities is CHF30.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Total Liabilities of CHF30.83 Mil. The current Total Liabilities is CHF30.83 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Total Liabilities is CHF30.83 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF26.30
Price